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Oxidative stress is intensely involved in enhancing the severity of various chronic respiratory 
diseases (CRDs) including asthma, chronic obstructive pulmonary disease (COPD), infections 
and lung cancer. Even though there are various existing anti-inflammatory therapies, which are 
not enough to control the inflammation caused due to various contributing factors such as anti-
inflammatory genes and antioxidant enzymes. This leads to an urgent need of novel drug 
delivery systems to combat the oxidative stress. This review gives a brief insight into the 
biological factors involved in causing oxidative stre s, one of the emerging hallmark feature in 
CRDs and particularly, highlighting recent trends in  various novel drug delivery carriers 
including microparticles, microemulsions, microspheres, nanoparticles, liposomes, dendrimers, 
solid lipid nanocarriers etc which can help in combating the oxidative stress in CRDs and 
ultimately reducing the disease burden and improving the quality of life with CRDs patients. 
These carriers improve the pharmacokinetics and bioavailability to the target site. However, 
there is an urgent need for translational studies to validate the drug delivery carriers for clinical 
administration in the pulmonary clinic.  
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S.No. Abbreviation Explanation  
1. COPD Chronic obstructive pulmonary disease 
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12. 3-NT 3-nitrotyrosine 
13. NSCLC Non-small-cell lung cancer 
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16. LOX Lipoxygenase 
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18. COX2  Cyclooxygenase 2 
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21. PIG3 p53 inducible gene 3 
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23. ERK Extracellular signal-regulated kinase 
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37. NO Nitric oxide 
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39. TBA-RS Thiobarbituric acid reactive species 
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45. HSPC Hydrogenated soy phosphatidylcholine 
46. SPC Soy phosphatidylcholine 
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49. Gold-PAMAM Polyamidoamine 
50. Gold-PPI Polypropyleneimine 
51. RNA Ribonucleic Acid 
52. CFTR Cystic fibrosis transmembrane conductance regulator 
53. SLN Solid lipid nanocarriers 
54. NLC Nanostructured lipid-based nanocarriers 
55. SLN-PTX Solid lipid nanocarriers-paclitaxel 
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57. PEG Polyethylene glycol  
58. ARE Antioxident response element 
59. GST Glutathione S-transferases 
60. GPX Glutathione Peroxidase 
61. DDS Drug delivery systems 
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63. TPs Transdermal patches 
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67. FeNO Fractional exhaled nitric oxide 
68. LABA long-acting b2-agonists 
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Introduction 
An imbalance between increased oxidative agents and antioxidant defense mechanisms is known 
as oxidative stress, which plays a critical role in the pathogenesis of multiple disorders, 
especially chronic respiratory disease like asthma, COPD, respiratory infections and lung cancer 
[1]. There are various external and internal factors, which can increase the severity of respiratory 
diseases (Figure 1).  
Studies involving asthmatics have demonstrated increased levels of reactive oxygen species 
(ROS) [2] and reactive nitrogen intermediates (RNI). These primarily include superoxide anions 
(O2
-), hydrogen peroxide (H2O2) and hydroxyl radicals (OH). The major external sources of 
oxidative stress in asthma include air pollution, pollens, cigarette smoke and the influx of 
inflammatory cells into airways post allergen exposure. Whereas, internal factors include 
mitochondrial dysfunction and metabolic factors such as obesity/metabolic syndrome [2, 3]. In 
addition, asthma patients also have depleted antioxidant defenses, including superoxide 
dismutase, glutathioneand catalase .An increase in the levels of oxidative stress, either 
exogenous (smoking, air pollution etc.) or endogenous (generated by immune cells such as 
macrophages, neutrophils and eosinophils) is linked to more severe asthma [4]. Whilst NADPH 
oxidase-dependent complex and the cytosolic xanthine oxidase system is involved in the 















derived ROS results in RNI burden [4, 5]. The crucial triggers of asthma exacerbations include 
respiratory infections, environmental pollutants and certain drugs (e.g., aspirin) [6]. These 
activate differential inflammatory profiles and in turn, differential oxidative burden during 
exacerbations [7]. Moreover, increased levels of oxidative stress markers (plasma lipid 
peroxides) have been reported in asthma patients experi ncing exacerbations [8]. 
Low levels of oxidative stress initiate the release of antioxidant and anti-inflammatory genes via 
the activation of nuclear erythroid 2 p45-related factor 2 (Nrf2). In nucleus, Nrf2 binds to and 
activates antioxidant response element (ARE) leadingupregulation of genes encoding 
antioxidant-detoxifying proteins, including antioxidants (GPx), thiol metabolism-associated 
detoxifying enzymes (GSTs) and stress-response genes (HO-1) [9]. Evidently, Nrf2 seems to be 
protective against cigarette smoke-induced COPD, as Nrf2-deficient mice exposed to cigarette 
smoke exhibited greater bronchoalveolar inflammation, enhanced alveolar expression of 8-oxo-
7,8-dihydro-2'-deoxyguanosine, increased apoptosis of endothelial and type II epithelial cells and 
most importantly, greater degree of emphysema when compared to control mice [10]. However, 
high intensities of oxidative stress trigger the activ tion of pro-inflammatory intracellular 
signaling leading to the expression of inflammatory c tokines, chemokines and adhesion 
molecules [11] resulting in increased airway inflammation and airway hyper-responsiveness. 
Although glucocorticosteroids remain the mainstay therapy for the management of asthma, they 
are not adequate to control oxidative stress-induce airway inflammation due to their ability to 
interfere with the expression of anti-inflammatory genes as well as antioxidant enzymes [12]. 
Hence, there is an urgent need to develop new strategies targeting oxidative stress to control or 
prevent airway inflammation. One potential approach could be the use of nanotechnology to 















COPD is a multi-factorial disease that is primarily caused by the external factors such as, 
cigarette smoking and/or exposures to biomass smoke, air pollution and a variety of occupational 
exposures to chemical dust and fumes. All these risk factors are also frequently implicated in the 
increases in the oxidative burden and ROS/RNI in the lungs, as well as systemically [15]. For 
example, airway smooth muscle cells from COPD patients exhibited increased ROS levels 
compared to healthy individuals [16]. Likewise, the n utrophils harvested from the peripheral 
blood of COPD patients have been shown to produce mor  ROS compared to healthy individuals 
[17]. Increased levels of ROS can then initiate myriad of biochemical reactions, leading to 
damaged cellular components (proteins, lipids, and nucleic acids). Moreover, ROS also initiates 
inflammatory cascades via multiple mechanisms, such as protein kinase pathways, transcription 
factors, and genomic expression of pro-inflammatory regulators. All these factors result into an 
‘over-activated’ immune system. Notably, the higher oxidative burden may lead to significant 
reductions in the VEGF levels in the lungs, which has been associated with the development of 
emphysema [17]. Inhalation of air pollutants results in the induction of oxidative stress in the 
lungs. For instance, inhalation of carbon particles present in air pollution, are retained by the 
lung tissues and induces oxidative stress [18]. Moreover, exposure to particulate matter from 
biomass/fossil fuels depletes anti-oxidants in cultured cells [19]. Occupational exposure (such as 
exposure to welding fumes) has been linked to significantly increased oxidative burden in the 
lung [20].  
Even though there arevarious options available for the treatment of COPD like PDE4 inhibitors, 
NF-κB inhibitors, MAPK p38 inhibitors, β2-agonistsand corticosteroids. However, none of them 















forinvestigationsfocusing on delivering such potential therapeutics directly to the small airways 
in reducing thedisease features and pathology of the disease. 
Respiratory infections, especially with Mycobacterium tuberculosis results in increased oxidative 
burden and inflammation in the lungs [21]. In addition, tuberculosis is also linked to increased 
risk of developing COPD [22]. Similarly, pulmonary infection with Streptococcus pneumoniae 
(common bacterial pathogen in CRDs) also induces oxidative stress that is depended on the 
pneumococcal auo lysin LytA, and independent of bacterial-derived H2O2 and pneumolysin [23]. 
Non-typeable Haemophilus influenzae (NTHi), also a major bacterial pathogen in CRDs, has 
been shown to induce ROS formation in human-derived primary cell lines (alveolar 
macrophages, human-lung fibroblast, and epithelial cell lines and blood-derived neutrophils) 
[24]. Moreover, mice infected with NTHi showed overproduction of oxidant, 3-nitrotyrosine (3-
NT) in the lungs [24]. Furthermore, respiratory viral infections also affect redox homeostasis, 
which has been reviewed by Khomich et.al .[25].  
Lung cancer is the leading cause of death amongst all cancers especially in men all over the 
world [26]. Lung cancer can be classified as Non-small-cell lung cancer (NSCLC) and small-cell 
lung cancer (SCLC). NSCLC contributes to 85% of all the lung cancers [27]. The causes of lung 
cancer are attributed to smoking, inhalation of polluted air, noxious gases like ozone (O3), 
sulphur dioxide (SO2), nitrogen dioxide (NO2) and micro-organisms. Cigarette smoke accounts 
for 90% of lung cancer deaths [28]. It has carcinogens including nitrosamines, acrolein, and 
poly- hydrocarbons. Along with, ROS/RNI produced from smoke contributes to cancer 
development. ROS initiates signaling cascades by activating the production of chemokines and 
cytokines thereby, causes chronic inflammation which up regulates nuclear transcription factor 















cyclooxygenase (COX2) [29]. It also activates oncogenes such as c-jun, c-myc and c-fos, further 
induces over-expression of c-jun has been reported to conciliate growth factors for NSCLC [30]. 
ROS/RNI also oxidizes protein and lipid moieties by carbonyl groups introduction in amino 
acids, the formation of protein-centered alkyls, malondialdehyde production etc. which 
eventually brings about the loss of histidine residues, oxidative scission, elevates mutagenesis 
and genotoxic products. Furthermore, these interact with DNA and modify polymerases, repair 
enzymes causing DNA- damage [31]. The most common DNA modification is 8-OH-G and is 
found to be 10 folds elevated in the urine of smokers [32]. In situations of inflammation in lungs, 
matrix metalloproteins (MMPs) interacts with growth factor, cytokines, chemokines, cell 
adhesion factors, apoptotic ligands, and angiogenic factors but over expression of MMPs induces 
tumor progression and metastasis [33]. During lung cancer, p53 is mutated causing defective 
apoptosis. p53 intervenes mitochondrial apoptotic signal by up-regulation of ROS [30]. The 
PIG3 protein responsible for oxidation-reduction, which is over-expressed in the tumor, thus fails 
to initiate apoptosis [34]. However, anti-oxidant therapy would contribute to balance oxidant 
levels in the body such as Thioredoxin (MOL-294) has been used against lung cancer, dietary 
supplements (Ascorbic acid, Vitamin E, β-carotene, Selenium etc.) reduce oxidative stress to 
some extent [35]. MMPs are an important component of the inflammatory cascade in lungs [33], 
therefore nano-formulation based targeted drug delivery or gene therapy has the potential to 
control disease progression and provide us with a better understanding. 
A variety of anti-oxidant therapies have been proposed for CRDs [36], however, their targeted 
delivery and efficacy remains a challenge for managing patients with CRDs. Targeting oxidative 















could indeed improve disease progression, survival and most importantly, quality of life in 
patients with chronic respiratory diseases. 
There is an emerging need of new therapeutic interventions, pharmaceutical agents, and drug 
delivery to target the oxidative stress, an important hallmark feature in various chronic 
respiratory diseases such as asthma, COPD, respiratory infections and lung cancer. Various 
natural and synthetic active moieties have been proposed with potent anti-oxidant and anti-
inflammatory properties in such diseases. The revolution in the area of drug delivery systems 
particularly the emerging concept of advanced controlled release drug delivery approaches such 
asmicroparticles, microemulsions, microspheres, nanop rticles, liposomes, dendrimers, lipid 
nanocarriers, solidlipidnanocarriers, nanostructured lipid carriers, are gaining massive attention 
and can help in combating the state of oxidative str s  in CRDs. The various novel drug delivery 
systems and approaches with their applications in targe ing oxidative stress are detailed below 
(Figure 1): 
1. Microparticles 
During the past decade, more attention has been given to the development of micro-particulate 
drug delivery carriers as these systems have better delivery of therapeutics to disease 
sites,particularly in treating pulmonary diseases [37, 38]. Particle size plays an important role in 
the delivery of drugs to the target site without affecting the non-target sites. It has been reported 
that the particle <0.5 µm cannot be retained in the airway for a prolonged time period due to the 
easy exhalation of such particles. On the other side particles with >10 µm diameter is suitable for 
deposition in the oropharynx. The microparticle in 1–5 µm size range is considered asanideal to 
















Amore et al. described alginate and chitosan-basedmucoadhesive solid lipid microparticles 
(SLMs) for the effective delivery of fluticasone pro ionate to treat chronic obstructive 
pulmonary diseases (COPDs). The developed SLMs weremo  effective in controlling oxidative 
stress-induced lung inflammation including ERK1/2 pathway activation and cigarette smoke 
extract-inducedsurvivin expression [39]. Lymphocyte-derivedmicroparticles (LMPs) stimulate 
oxidative stress in endothelial cells [41]. Qiuet al.(2014) identified that LMPs cause apoptosis of 
alveolar epithelial and bronchial cells by the activation of p38 mitogen-activated protein kinase 
signaling with an increase in cellular oxidative stre s and arachidonic acid production [42]. 
The first report on the expression of lung vascular endothelial growth factor in 
benzo(a)pyrenefed mouse model ofa lungtumour was published by Bandi and co-workers. PLGA 
microparticles released budesonide in a sustained manner for over 21 days. Microparticles have 
also showed potential of inhibiting the angiogenic fa tors in lung cancer on local delivery with a 
sustained release in benzo(a)pyrene-fed mice. This in btion resulting is attributed to the reduced 
malondialdehyde accumulation, glutathione depletion, vascular leakage, and vascular endothelial 
growth factor and c-myc expression.Inhibition of oxidative stress by the developed 
microparticles is especially beneficial in treating tumours [43]. 
In a study, Yooet al. fabricated porous poly(lactide-co-glycolide) microparticles by water-in-oil-
in-water multi-emulsion method for effective pulmonary delivery of anthocyanin. Ammonium 
bicarbonate and starch were used as a porogen and viscous additive, respectively. Prolonged 
residence (up to 20 days) of anthocyanin was recordd in lung epithelium of BALB/c mice. The 
microparticles showed a sustained in-vitro release profile of anthocyanin and antioxidant activity 















have been recommended as a potential drug delivery car ier for effective relief of oxidative stress 
in pulmonary diseases like COPD [44]. 
Porous polymeric (vanillyl alcohol-containing copoly xalate - PVAX) microparticles containing 
dexamethasone as a therapeutic agent to treat airway infl mmatory diseases have been reported 
by Jeonget al. The drug-loadedmicroparticles significantly reduced oxidative stress level and 
inhibited expression of pro-inflammatory tumor necrosis factor-alpha (TNF-α) and inducible 
nitric oxide synthase in the lungs of ovalbumin-challenged asthmatic mouse models. The results 
suggested the potential applicability of PVAX based porous microparticles as therapeutic 
systems in treating asthma [45]. 
It has been established that in-vitro exposure of human alveolar cells to hydrogen peroxide 
causes microparticle generation by p38 activation. Neri et al. reported inhibition of p38 
phosphorylation-dependenthydrogen peroxide-induced microparticlesin alveolar cells by 
pirfenidone. Pirfenidone inhibited hydrogen peroxide induced microparticle generation in both 
flow cytometry and solid phase thrombin generation methods. Inhibition of p38 mediated 
procoagulant microparticle generation by pirfenidone has been disclosed first time by these 
researchers [46]. 
The fundamental mechanism of tungsten oxide microparticle and nanoparticle toxicity has been 
reported in human lungcarcinoma (A549) cells. The aver ge size of synthesized microparticles 
and nanoparticles was 3.88 µm and 53.84 nm, respectively. Nanoparticles reduced cell viability 
and membrane damage in a dose-dependent manner. A significant gain in tail DNA and 
micronuclei formation was observed after 24 h. The DNA damage induced by tungsten oxide 
nanoparticles could be due to the increased level of inflammation and oxidative stress, which is 















content, catalase. Nanoparticles inhibited G2/M phase of the cell cycle. The results showed that 
themicroparticles did not instigate toxic effects [46]. 
Spray driedresveratrol and budesonide inhalable microparticles have been reported for effective 
therapy of chronic lung diseases. Cytotoxicity studies of the microparticles were carried outin rat 
alveolar macrophages. The formulations were further ested to access the biological response of 
alveolar macrophages in terms of cytokine expression , free radical scavengingand nitric oxide 
production. The results showed that the alveolar macrophages toleratedresveratrol and 
budesonide. The microparticles decreased interleukin-6 (IL-6) and (TNF-α) levels in 
lipopolysaccharide-induced alveolar macrophages [47].
Bot et al. investigated the applicability of lipid-based hollow and porous spray dried 
microparticles (PulmoSpheres™) for the effective delivery of human immunoglobulin. An 
improved release profile of immunoglobulinwasobservedfrom the synthesized microspheres once 
added to an aqueous environment. The results show systemic bio-distribution of 
microparticlesinupperand lower respiratory tract of BALB/c mice .Also, the receptor-mediated 
loading of alveolar macrophages relates to the enhanced immune responses against xenotypic 
epitopes was observed. The formulation approach is ompatible with local and systemic delivery 
via there respiratory mucosa [48]. Vehring et al. reportedformoterol fumarate dihydrate, 
mometasonefuroate or glycol pyrrolate, containing porous phospholipid microparticles delivered 
using 1,1,1,2-tetrafluoroethane as a propellant. The formulation containing drug microcrystals 
associated with porous particles improved suspension tability than the suspensions without 
















Microemulsions are gaining popularity due to their unique propertiessuch as ease of preparation, 
stability, clarity, increased bioavailability etc. [50]. Akhuemokhan et al. formulated 
microemulsion (ME) of fluticasone propionate (FP) for pulmonary delivery using mesh or jet 
nebulizers and compared with the marketed nebuliser uspension of the same drug 
(Flixotide®nebules). Jet nebuliser effectively delivered the drug, while the mesh nebuliser failed 
to deliver the microemulsion. The delivery of microemulsion from the nebulizer was controlled 
by the viscosity, particle sizeand aerodynamic particle size distribution. The aerodynamic 
particle size distributions produced by microemulsion  using a jet nebuliser showed these to be 
promising results [51]. 
Effective pulmonary delivery of atorvastatin from solid self-microemulsifying drug delivery 
system (S-SMEDDS) has been reported. The attempt for prepare microemulsion (ME) was 
firstly done using isopropyl myristate (IPM). The microemulsion was examined for 
physicochemical characterization, phase diagram, and stability studies. The microemulsion was 
spray dried to obtain solid S-SMEDDS using a combination of sugars and leucine with or 
without polyethylene glycol 6000. In-vitro cytotoxicity studies were carried out for both the 
formulations (microemulsion and S-SMEDDS) using a lung cancer cell line. Lecithin/TPGS 
(1:3), lecithin/oil (1:1) and surfactant/co-surfactn  (1:1) were identified as optimized ratios for 
the formulation of the microemulsion. The improved cytotoxic activity on lung cancer cells was 
observed when the atorvastatin was deliveried with d-α-tocopheryl polyethylene glycol succinate 
in S-SMEDDS [52]. 
Mikhail et al. reported improved and more consistent absorption of Neoral and Sandimmun 
(cyclosporin) from microemulsion in patients with lung transplants for cystic fibrosis. The results 















immunosuppression effect of microemulsions containing tacrolimus and cyclosporin in 413 adult 
lung transplant recipients. Tacrolimus was found to be superior to cyclosporinwith respect to the 
incidence of lymphocytic bronchitis score, bronchiolitis obliterans syndrome, arterial 
hypertension, and treatment withdrawal. More frequent diabetes mellitus was reported in patients 
who received tacrolimus when compared with the patient's received cyclosporin. No significant 
difference was observed in mortality between tested groups [54]. 
The applicability of etoposide, coix seed oil, and ginsenoside Rh2 containing microemulsion 
(ECGME) in lung cancer treatment has been validated an  the mechanism underlying the 
enhanced antitumor efficacy has been explored. Ginsenoside Rh2 (G-Rh2) (3% w/w) was 
selected as optimum concentration to formulate microemulsion with small particle and high drug 
encapsulation efficiency. The intracellular fluoresc nce of human non-small cell lung cancer 
cells treated with fluorescein isothiocyanate-labeled microemulsion was significantly higher. In 
vivo anticancer study results showed significant inhibition non-small cell lung cancer tumor 
xenograft growth and induced tumor cells apoptosis in mice treated with microemulsion [55]. 
Oral bioavailability of the quercetin, a plant-derived anti-oxidan tand anti-inflammatory agenthas 
significantly improved frommicroemulsionwhen compared tothe suspension in an experimental 
mousemodel of airways allergic inflammation. After immunization with ovalbumin, the animals 
received daily oral doses of microemulsion (3 or 10 mg/kg body weight in an oil-in-water 
microemulsion content 0.02:0.2:1 of lecithin:castoroil:Solutol HS15®), suspension (10 mg/kg 
body weight in carboxymethylcellulose 0.5% in water)or vehicle for a period of 22 days. The 
control group received dexamethasoneasa positive control drug. Orally administered suspension 
failed to interfere with leukocytes, while microemulsion inhibited leukocytes in a dose-















treated with microemulsion. However, it failed to interfere with chemokine (CCL11), cytokines 
(IFN-γandlipid (LTB4) levels. Microemulsion also inhibited the activation of nuclear 
transcription factor kappa B, P-selectin expression and the production of mucus in lungs [56]. 
3. Microspheres 
Microspheres are small and spherical particles with1–1000 µm diameters [57]. The influence of 
the reactive oxygen species (ROS) scavenger Tempol on pulmonary hypertension has been 
described by Mizera et al. They described NO synthase activity and production of NO oxidative 
products (NOx) after pulmonary embolism (PE).  When Sephadex microspheres suspended in 
PSS were applied in right jugular vein as the pulmonary microembolism, thechanges in perfusion 
pressure in isolated salt solution-perfused lungs, the activity of NO synthase and NOx plasma 
concentration were measured in rats. Tempol was applied intraperitoneally before pulmonary 
embolism which demonstrates the significant reduction in the basal perfusion pressure [58]. 
The selective pulmonary vasodilation effect of soluble guanylate cyclase and a low dose of 5-
Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 
41-2272) has been reported in dogs with an acute pulmonary embolism. Evaluation of arterial 
blood gas and hemodynamic were carried out in non-embolized vehicle treated dogs and in 
embolized dogs treated with intravenous injections of BAY 41-2272 microspheres. 
Thiobarbituric acid reactive substances and plasma cyclic guanosine 3',5'-monophosphate 
concentrations were determined byafluorometricand a commercial enzyme immunoassay 
method, respectively. A decrease in pulmonary artery p essure and pulmonary vascular 
resistance was recorded in animals treated with BAY 41-2272 [59]. 
The effects of sildenafil on the hemodynamic changes caused by acute pulmonary embolism 















pulmonary embolism was induced by intravenous injections microspheres (300 µm) to increase 
mean pulmonary artery pressures by 20mmHg. Plasma thiobarbituric acid reactive species were 
determined to measure oxidative stress. Sildenafil was found toreduce mean pulmonary artery 
pressures in dogs and attenuated the increase in oxidative stress after acute pulmonary embolism. 
Similar results were  recorded in rat isolated perfused lung preparation [60]. 
Souza-Costa et al. analyzed the hypothesis that L-arginine would reduc the strength of oxidative 
stress and pulmonary hypertension during acute pulmonary embolism. The study involved 
isolated lung perfusion rat models of acute pulmonary embolism. Sephadex microspheres were 
injected into the pulmonary artery. The oxidative stre s and NO production were recorded based 
on the results of thiobarbituric acid reactive species (TBA-RS) and nitrite/ nitrate (NOx) 
concentrations obtained. L-Arginine reduces the strngth ofacute pulmonary embolism-induced 
pulmonary hypertension by about 50% through antioxidant mechanisms with increased NO 
synthesis [61]. 
4. Nanoparticles 
These are the particles having a size range of 1-100nm and are the new approach for targeted 
delivery of the drugs [62]. Nanoparticles due to its small size have a tendency to behave as 
vessels for drugs, which in turn can reach any region of the humanbody [63]. The Intracellular 
cell adhesion molecule-1 (ICAM-1) and platelet endothelial cell adhesion molecule (PECAM) 
receptors present over the endothelial cells of pulmonary airways are targeted by these 
nanoparticles. Therefore, these can be used as carriers for NADPH oxidase (NOX) inhibitors, 
superoxide dismutase (SOD) and catalase in order to p event oxidative stress in the respiratory 
system [64]. Muro et al. demonstrated that delayed the intracellular accumulation of anti-ICAM-















cells of the airways. These nanoparticles are uptaken by the endothelial cells and remain there for 
1hr and then delivered to lysosomes after 2-3hrs for degradation. Due to this delayed delivery to 
lysosomes, the antioxidant activity of catalase is extended and thus is able to prevent any 
oxidative injury to the lungs [65]. Pu and co-workers discovered the potential of curcumin-
loaded nanoparticles in treating oxidative stress and inflammation. Upon release, curcumin 
decreases the surplus amount of oxidants formed by lipopolysaccharide (LPS)-stimulated 
macrophages (Figure 2). Thus, these have the capability of targeting disorders associated with 
oxidative stress [65]. Chen et al developed nanoparticles encapsulated with Cerium oxide, also 
known as nanoceria and determined their potential as n antioxidant. As it contains both Ce3+and 
Ce4+ ions, it causes redox reactions that are responsible for reducing the level of ROS [66] 
(Figure 2). 
5. Liposomes 
Liposomes are the drug delivery system suitable for encapsulation of both hydrophilic and 
lipophilic drugs. Liposomes are attracted towards pulmonary delivery, following inhalation local 
drug effect is observed in the lungs with prolonged duration of action [67, 68]. Liposomal 
constituents phospholipids, cholesterol used in liposomes preparation are typically analogous to 
pulmonary surfactants in mammals [69, 70]. Many repo ts suggest liposomal constituents are 
found to compatible with alveolar macrophages, hydrogenated soy phosphatidylcholine (HSPC) 
and soy phosphatidylcholine (SPC) liposome exposure for prolonged nebulization 
(concentrations up to 150mg/mL) has no effect on the lungs of sheep.  Liposomes found to be 
safe for inhalation in studies performed on human volunteers. Studies reveal liposomes are 















liposomal formulation containing amikacin by Insmed’s (Arikace®) in nebulized form is one of 
the FDA approved formulation [72]. 
Chennakesavulu and co-workers investigated the delivery of colchicine and budesonide 
encapsulated in liposomes for Idiopathic Pulmonary Fibrosis. Thin layer film hydration method 
was used for preparation, optimized formulation means particle size was 100 nm. The 
formulation is lyophilized by addition of mannitol as cryoprotectant and carrier. In-vivo efficacy 
studies were performed in adult male Wistar rats. Liposomal dry powder for inhalation 
prolonged drug retention in lungs with reduced systemic absorption. The liposomal lyophilized 
powder was stable for 6 months at 25 ± 2°C 60% ± 5% RH and refrigerated conditions (2 - 8 °C) 
[73]. 
These are the drug delivery systems used for distribution of both hydrophilic and lipophilic anti-
oxidants for the management of diseases related to oxidative stress. Suntres showed the potential 
of Glutathione-loaded liposomes as an antioxidant for the treatment of hypoxia-associated lung 
damage or paraquat-induced lung injury. During pre-clinical trials, it was found that 10% of the 
dose of liposomes was retained in the lungs for 24-48 hours following treatment and pulmonary 
retention was enhanced by 18%. Thus, prolonged retention causes decreased discharge of 
glutathione from liposomes.  He also proved that liposomes encapsulated with N-acetyl cysteine 
(NAC) showed the anti-oxidant property. As a result of NOS-induced lung damage, NAC 
initiates MAPK (Mitogen-activated protein kinase) pathway and decreases inflammatory 
responses (Figure 3). When these liposomes are taken via IV route, their half-life was increased 
from 6min to 30 min. Thus, these enhance the duration time of the drug in the target organ [69]. 
Glavao et al. prepared cationic liposomes encapsulated with ceftriaxone and three antioxidants 















the lung damage caused by sepsis and improves survival rate in rats. They also decrease 
nitrates/nitrites level and increases the life of alveolar macrophages [74] (Figure 3). 
6. Dendrimers 
These are the branched systems containing a center area surrounded by star-shaped branches. 
Various ligands could be attached at the surface for targeted release [75]. Esumi and co-workers 
developed Gold-PAMAM (Polyamidoamine) dendrimers and Gold-PPI (Polypropyleneimine) 
dendrimers by reduction of HAuCl4 with sodium borohydride and compared their antioxidant 
action. These dendrimers act by terminating the oxidative action of hydroxyl radicals. The 
catalytic activity of these dendrimers depends on the type of terminal group present over them. 
Gold-PAMAM dendrimers were found to have more antioxidant activity than that of Gold-PPI 
dendrimers. When their activity was compared with ascorbic acid, the rate constant of Gold-
PAMAM dendrimers was 85 times more than ascorbic acd. Thus, these have the potential of 
being used as a drug delivery system for targeting oxidative stress [76]. Feliu et al. prepared 
cationic poly (amidoamine) dendrimers (PAMAM-NH2) using RNA sequencing and 
computational approaches. These cause down-regulation of genes related to cell cycle at low 
doses and is uptaken by lung cells and resides in lysosomes. Thus, biological methods help for 
the prediction of cellular responses to these delivery systems [77]. Brockman et al developed 
dendrimers containing cysteamine i.e. an autophagy-inducing drug having bactericidal activity. 
These prevent ∆F508 mutation in Cystic fibrosis transmembrane conductance regulator (CFTR) 
gene which is involved in causing cystic fibrosis. It also reduces Pseudomonas aeruginosa 
development and causes breakdown of the mucus. This system enhances bioavailability and 















7. Lipid Nanocarriers: 
Lipid-basednanocarriers are the drug delivery system widely used for lipophilic drug delivery. 
Solid lipid nanocarriers (SLN), nanostructured lipid-based nanocarriers (NLC), liposomes are 
widely used nanocarriers in drug delivery. Lipid-based nanocarriers have several advantages in 
comparison to polymeric nanocarriers, lipid used in na ocarriers are non-toxic, free from organic 
solvents, exhibit good tolerability in air-ways and lipids used are of biodegradable [79]. 
 The nanosize of the lipid particles are easily aerosolized, they exhibit adhesion, accumulation, 
and retention in the lungs as well as prolong the drug release. These are ideal properties of the 
lipid nanocarriers make advantage in case of pulmonary drug delivery [37]. Lipid nanocarriers 
are more prone to adsorption on to the epithelium which helps to escape from mucociliary 
transport [80]. 
8. Solid Lipid Nanocarriers: 
Solid lipid nanocarriers are next-generation lipid nanocarriers of emulsion-based formulations 
where liquid oil is replaced with solid lipid. Solidnanocarriersprotect encapsulated drug, provide 
controlled release of the drug, with enhanced physical stability. Large-scale batches can be 
formulated in case of SLN using high shear homogenizer Solid lipid nanocarriers can overcome 
the limitations of liposomal drug delivery systems [37]. Liposomes cannot withstand the shear 
force exerted by nebulizer, physical stress gets applied on to the liposomal bilayer when aqueous 
dispersion is converted into the respirable aerosol formulation. This leads to loss of originally 
entrapped drug, this can be overcome by SLN based formulations [81]. 
Han and his co-workers encapsulated green fluorescence protein plasmid (pEGFP) and 















transferrin-containing ligands for targeted delivery of drug and gene in lung cancer. In-vitro 
efficiency was evaluated in human alveolar adenocarcinoma cell line (A549 cells) whereas 
in vivo transfection efficiency was evaluated in mice bearing with A549 tumors. The particle 
size of optimized nanoformulation was 267 nm whereas the surface charge of nanocarriers was 
+42mV. There was a remarkable therapeutic effect both in the delivery of plasmid (gene) and 
drug doxorubicin. Ligand coating of nanocarriers improved therapeutic efficiency of the carriers 
targeting lung cancer cells in combination delivery of gene and a chemotherapeutic agent [82]. 
Videira and colleagues formulated solid lipid nanocarriers (SLN) of paclitaxel to enhance 
solubility and delivery to lungs. The SLN based formulation increased the accumulation of drug 
at the target site (in lung cancer) which resulted in augmentation of paclitaxel therapeutic index. 
Compared with marketed formulation Taxol®, SLN loaded paclitaxel was found 20 folds higher 
cytotoxic effect. Lipid content of SLN based nanoparticulate systems improves permeation 
through the cell wall, which leads to an escalation in cellular internalization of drug loaded in 
SLN. Increase in cellular internalization is expected for enhanced cytotoxicity response of SLN 
based particles. SLN loaded paclitaxel inhalation exhibited improved efficacy in comparison to 
intravenous administration of Taxol® in experimental metastasis stage of tumor model. 
Pulmonary administration of SLN-PTX by inhalation has high therapeutic efficacy within 2-
weeks, metastases in the lung surface were reduced to a substantial level. On the extension of a 
treatment, the tumor was completely disappeared [83]. 
Wang et al. developed curcumin loaded SLN by the solvent-injection method and its efficacy 
was tested in ovalbumin (OVA)-induced asthma models. The size of optimized nanoparticles 
based formulation was 190 nm, with -20.7mV zeta potential, entrapment of curcumin was found 















developed in the rat, a high concentration of curcumin was observed in lungs and liver in case of 
SLN formulations. In-vivo administration of curcumin loaded SLNs shown prominent inhibition 
of T-helper-2 type cytokines interleukin-4 and interleukin-13. In comparison to curcumin alone, 
SLN based formulations exhibited active suppression of hyper responsiveness and infiltration of 
inflammatory cells. The study reveals SLN based formulations as better delivery system 
strategies for the treatment of asthma [84]. 
Hu et al. prepared SLN of epirubicin inhalable formulation for lung cancer. In-vitro studies 
revealed formulations remains stable while nebulization and the respirable fraction was 
improved compared to the solution. There was no cyttoxicity of blank SLN on A549 alveolar 
epithelial cells. In-vivo studies revealed increased drug concentrations in lungs in case of SLN 
compared to epirubicin solution for treatment of lung cancer [85]. 
 
9. Nanostructured Lipid Carriers: 
Solid lipid nanocarriers exhibit limitations such as low potential drug loading and on storage,low 
ordered lipid modification is transformed to highly ordered β-modification. This leads to few 
imperfections in by perfect crystal lattice which leads to drug expulsion on storage. 
Nanostructured lipid carriers are next generation to SLN in which solid lipid is mixed with liquid 
lipid at the ratio of 70:30 to 99.9:0.1. By the addition of the liquid lipid to the solid lipid matrix, 
it maintains lipid in a less ordered form which improves drug loading and stability of 
nanocarriers (decrease drug expulsion) [86].  
Moreno-Sastre and co-workers worked on nanostructured lipid carriers (NLC) for pulmonary 















and particle size of optimized formulation was 250 nm with 93% encapsulation efficiency. Lipid-
based nanoparticles labeled with infrared dye were us d for in-vivo administration studies in 
BALB/c mice. Formulations labeled using infrared dye were administered using MicroSprayer™ 
aerosolizer after suspending in phosphate buffer saline. It was instilled by spraying into lungs 
with help of syringe plunger. After immediate administration nanoparticles dispersed in entire 
lungs, after 2 hours drug administration was found to systemic and detected in kidney and liver 
and it was less intense in the spleen. After 48 hours drug was disappeared in other organs and 
remained in lungs were as free drug cleared faster to other organs and there was no presence of 
the drug in lungs. Apart from the improved sustained r lease of drug from NLC formulations,in-
vitro studies revealed there was no effect on cell viability. The in-vitro study was performed to 
check the effect of mucus on nanocarriers by application of artificial mucus layer, which 
revealed the mucus layer has no effect on SLNs [87].
Patil-Gadhe et al. formulated montelukast loaded NLC for pulmonary applications. The 
optimized formulation with particle size 184.6±2.7 nm with >95% encapsulation was subjected 
to lyophilization for inhalable dry powder by adding 3% mannitol. The lyophilized powder 
density was 0.051±0.002 g/cc with a mass median mean diameter of 15.1 ± 1.4 µm. The in-vivo 
studies in Wistar rat revealed amplified bioavailability, with longer residence and targeting factor 
11.76 times in comparison to montelukast aqueous solution. This suggested NLC based dry 
powder for inhalation improve efficacy with reduced toxicity [88]. 
Pardeike and colleagues developed NLC based formulations of itraconazole, optimized 
formulation exhibited 98.78% entrapment. Tonicity of the formulation was adjusted with 















was burst release of drug from the optimized formulation. Using jet stream and an ultrasonic 
nebulizer there was no effect on size and entrapment of nanocarriers [89]. 
Patlolla and co-workers developed NLC of celecoxib by high-pressure homogenization. The 
particle size of the optimized formulation was 217±20 nm and >90 % entrapment. Fine particle 
fraction and median mass aerodynamic diameter were found to be 75.6+/-4.6 and 1.6+/-0.13µ in 
in-vitro aerosolization studies. In-vivo studies were performed in Balb/c mice, celecoxib NLC 
formulations showed 4 fold increase in AUC(t)/D in lu g tissue compared to celecoxib solution. 
The systemic clearance of celecoxib solution was 20.03 liter/hour were as celecoxib NLC 
clearance was 0.93 liters/hour. The study reveals improved bioavailability with minimal dosing 
interval [83].  
 
 
Miscellaneous   
Mucoadhesive drug delivery system  
Mucoadhesive drug delivery is mediated by the interaction between the mucus layer over the 
mucosal epithelial, mucin moieties and polymer/co-polymer with increased dosage residence 
time to the site of absorption [90]. This system is beneficial over other srug delivery systems 
(DDS) including oral controlled drug release as it has increased residence time in the 
gastrointestinal tract, better targeting at the specific site and elevated flux of drug at the target 
site. The nasal cavity has a mucosal layer of 150-200 cm2 allowing a residence time of 15-30 min 
to particulate matter. Increased residence time elevates the mucociliary activity due to the 















polymer/copolymer absorbs water from the mucosal layer followed by penetration into the 
mucus for localization of drug in the nasal cavity, forming a gradient across the membrane for 
controlled drug release [91, 92]. Co-polymers are us d for nasal based mucoadhesive DDS such 
as poly (amidoamine) dendrimer, methylcellulose, hydroxyl ethyl cellulose, poloxamer, poly 
(vinyl pyrrolidone), thiolated poly (acrylic acid), poly (dimethyl siloxane) etc [93-96].  
In a study by Zhang Lan et al. fabricated mucoadhesive DDS based budesonide in chitosan 
microparticle and characterized drug release and the features of theallergic asthma using mice 
model. The therapeutic action was identified by measuring the IL-4 and IL-5 in bronchoalveolar 
lavage and mRNA. From this study, it is evident that drug release lasted for 12 or 18 hr 
depending on the molecular weight of chitosan. It is also reported that after consecutive seven 
days of treatment, eosinophil number and IL-4 & IL-5 in mRNA was found to be decreased. 
Mucoadhesive DDS chitosan-budesonide decreases the drug dose by 50% for effective treatment 
[97, 98]. 
Anotherstudy by Suk et al. reported the use of mucolytic adjuvant including N-acetylcysteine 
(NAC) and recombinant human deoxyribonuclease (rhDNase) to deliver highly compact DNA 
nanoparticle in the treatment of cystic fibrosis (CF). Furthermore, it was reported that PEGylated 
NAC and combination of NAC with rhDNase nanoparticles penetration increased by 3 and 6-
folds repectively [99, 100]. Another strategy of mucoadhesion phenomenon is by coating 
mucolytic agents over the surface of nanoparticles such as the use of DNase which cleaves the 
accumulated DNA in the mucus of CF, non-specifically [101].   
Montelukast loaded xyloglucan microspheres have been considered ideal lung delivery as DPI 















microspheres. It has been suggested that the residence time of Montelukast-xyloglucan 
microsphere is 6 h and has a low frequency of drug administration. It has been reported as an 
ideal system for antihistamine delivery via pulmonary route [102, 103].  Ruge t al. reported that 
mucoadherent particles do not disintegrate in static condition while it only occurs when particles 
are bound to mucus. Therefore, mucociliary clearance forces play role in particle disintegration, 
thus such a combination can be utilized for pulmonary gene therapy [104, 105]. 
Transdermal patches: 
 The largest organ in the human body by mass is skin with a surface area of 16.1-21.5 sq. ft. 
transdermal patches (TPs) has various advantages over c nventional drug delivery such as a 
potential alternative to hypodermic injection and oral drug delivery systems that can also be used 
for drugs which undergo rapid first-pass metabolism with better patient compliance[106] . 
Kim and et.al. Studied the effective use of adrenergic β2 receptor agonist tulobuterol TPs for 
prophylactic treatment in asthma and COPD, the application of TPs has shown decreased airway 
resistance (Raw) and increased dynamic lung compliance (Cdyn) in clinical study. Katsunuma T et
al proved that TPs can be used for continues and short-term therapy for pediatric asthma [107], 
especially which are undergoing leukotriene receptor antagonist (LTRA) therapy, and the results 
showed a tremendous rise in  volume of peak expiratory flow (% PEF) without intensifying 
fractional exhaled nitric oxide (FeNO) [108]. Another study by Mochizuki et al involved testing 
the effectiveness of TPs in elderly people (H)have proved that elderly people with COPD when 
treated with TPs and inhaled long-acting b2-agonists (LABA) salbutamol, showed an adherence 
rate of 90.3 1 1.6% for TPs whereas 75.5 1 2.9% for LABA. Such studies clearly demonstrate the 
















Investigating the role of oxidative stress in CRDs like asthma, COPD, respiratory infections and 
lung cancer can help in designing potential and better therapy for CRDs. The concept of novel 
drug delivery systems and approaches such as microparticles, microemulsions, microspheres, 
nanoparticles, liposomes, dendrimers, lipid nanocarriers, solid lipid nanocarriers, nanostructured 
lipid carriers has shown a tremendous revolution in the recent times with an emerging potential 
for CRDs when blended with the biological discoveries to target oxidative stress and ultimately 
reducing the diseases pathology. The discussed delivery methods such as nebulization and dry 
powder inhalation of the nanoparticle and microparticle drugs are advantageous as they escape 
mucociliary clearance and can encounter the deep target sites. There are various future 
challenges, whichstill warrant attention in combating the oxidative stress in CRDs using drug 
delivery, which is underway. Rigorous studies are being done to maximize drug delivery and 
minimize the toxicity, which includes modification of surface by PEG, mucolytic agents, 
osmotic pressure gradient for improved penetration hrough mucus by using mannitol and 
optimization of the formulation to upgrade the stability, deep lung deposition, and distribution. 
Several physiochemical characteristics of the drug formulation influence the pulmonary drug 
delivery including the size of particle, charge, morphology, and biodegradability. However, the 
concept of drug delivery targeting at the cellular and molecular level using the novel drug 
delivery concepts are providing a new direction to the pulmonary clinic providing better 
treatment, maximal patient compliance with minimum side effects. 
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1. Fig. 1. Various internal and external factors which enhance oxidative stress in the lungs, 
eventually increasing the severity of CRDs. 
2. Fig 2.The action of Curcumin over NADPH oxidase 
















Fig. 1. Various internal and external factors which enhance oxidative stress in the lungs, 



































































1.      Oxidative stress level contributes to severity of chronic respiratory diseases. 
2.      Delivery of new antioxidant therapies via novel drug delivery is urgently needed. 
3.      Novel vesicular drug delivery systems are gaining attention in targeting oxidative 
stress. 
4.      Vesicular drug delivery provides improved patient compliance and fewer side effects. 
 
